Effect of carnitine on patients with heart failure: an evidence-based case report

Yosua Yan Kristian, Wiji Lestari


Background: Heart disease is one of the leading causes of death in Indonesia. Nutritional management plays an important role in overcoming heart disease, both as prevention and treatment. Carnitine plays a role in fat metabolism and can reduce the formation of thrombosis, resulting in improved heart function and quality of life of patients.

Objectives: This study is aimed to identify the effect of carnitine in patients with heart failure.

Methods: Existing research findings and articles are selected based on inclusion and exclusion criteria in three databases, namely PubMed, Cochrane and Wiley. The outcome were functional capacity and heart function.

Results: One meta-analysis that address with the clinical questions was obtained, and based on that article, giving carnitine to patients with heart failure has effects on increasing functional capacity, heart function, BNP serum and NT-proBNP levels. However, no effects found on mortality. Furthermore, no significant side effects on carnitine was found.

Conclusions: Carnitine supplementation at a dose of 1 up to 6 g/day has a positive impact on functional capacity, heart function, BNP serum and NT-proBNP levels in patients with heart failure, alongside with minimal side effects.


carnitine; heart failure; outcome

Full Text:



World Health Organization. Regional Office for the Western Pacific‎. The Asia-Pacific perspective : redefining obesity and its treatment. Sydney: Health Communications Australia; 2000. Available from: https://apps.who.int/iris/handle/10665/206936.

Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 2014;63:1123-33.

Reyes EB, Ha JW, Firdaus I, Ghazi AM, Phrommintikul A, Sim D, et al. Heart failure across Asia: Same healthcare burden but differences in organization of care. Int J Cardiol 2016;223:163-7.

Wang ZY, Liu YY, Liu GH, Lu HB, Mao CY. l-Carnitine and heart disease. Life Sci 2018;194:88-97.

Borum PR. Carnitine in parenteral nutrition. Gastroenterology 2009;137:S129-34.

Lapillonne A, Fidler Mis N, Goulet O, van den Akker CHP, Wu J, Koletzko B, et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Lipids. Clin Nutr 2018;37:2324-36.

Kinuagasa Y, Hirai M, Yanagihara K, Haruki N, Matsubara K, Kato M, et al. Carnitine Paradox in Patients With Heart Failure. Journal of Cardiac Failure 2017;23

Writing Committee M, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240-327.

Jing Z-C, Wu B-X, Peng J-Q, Li X-L, Pan L, Zhao S-P, et al. Effect of intravenous l-carnitine in Chinese patients with chronic heart failure. European Heart Journal Supplements 2016;18:A27-A36.

Shang R, Sun Z, Li H. Effect dosing of L-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2014;14:88.

Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int 2017;2017:6274854.

Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83.

DOI: https://doi.org/10.25220/WNJ.V04.i1.0003


  • There are currently no refbacks.

Copyright (c) 2020 Yosua Yan Kristian, Wiji Lestari

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

View My Stats